secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0001193125-22-221213
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Q2 net loss $3.0M; cash $38.5M; FB-102 on track for late 2023/early 2024
------------------------------------------------------------------------------

- Net loss $3.0M for Q2 2022 ($0.21 per share), compared to $5.8M loss ($0.43) in Q2 2021.
- Cash and equivalents $38.5M as of June 30, 2022; raised $7.0M via ATM in July/August.
- R&D spend down to $1.0M from $3.5M YoY as FB-401 wound down; focus shifting to autoimmune pipeline.
- Lead candidate FB-102 expected to enter clinic late 2023 or early 2024 for GvHD, vitiligo, alopecia areata.
- Appointed Hubert Chen as CSO and President; added Stephen Doberstein to board of directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312522221213/0001193125-22-221213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312522221213/d303551d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-221213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer